ArticleCureus2025
Trend, Epidemiology, and Clinical Characteristics of Vulvar Cancers in Lagos, Nigeria: A Facility-Based Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Vulvar cancer (VC) is a rare gynecological cancer (GC) that is not commonly studied. Because of its location, vulvar symptoms are not frequently brought to the clinician's attention. Many women are not aware of VC and frequently attribute its early symptoms to other benign causes. In addition, little is known about the disease epidemiology and clinical characteristics in Lagos, Nigeria. Objectives Our study aimed to describe the trend, epidemiology, and clinical characteristics of VC in Lagos, Nigeria. Materials and methods Records of women with VC who presented to Lagos University Teaching Hospital between January 2010 and December 2019 were retrieved, and information on their socio-demographic and clinical characteristics was obtained for analysis. Data analysis was done using IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp. Results VC accounted for 4.0% of all GC managed in the hospital. There was a rising trend in the number of VCs managed during the study period, with 75.9% of cases managed in the last five years. The mean ± SD age of women with VC was 52.2 ± 11.8 years, with 27 (60.0%) above 50 years old. The majority had low-level occupations, 35 (77.8%), multiple sexual partners, 29 (64.4%); history of genital warts, 35 (77.8%); vulvar skin lesions, 40 (88.9%), and were menopausal, 26 (57.8%). The most common presenting symptom was vulvar swelling 32 (71.1%) and 20 (44.4%) presented with stage III disease. Squamous cell carcinoma was the most common histological type, 35 (77.8%), while the use of only surgery, 15 (33.3%), chemotherapy, 4 (8.9%), radiotherapy, 4 (8.9%), and chemoradiation, 4 (8.9%), were the most common treatment modalities. Conclusion VC accounts for 4.0% of GC in Lagos, Nigeria, and its prevalence is rising. Women with VC are usually advanced in age, postmenopausal, have a history of multiple sexual partners, and frequently present in advanced-stage disease. There is a need to increase awareness about the disease and support its care to improve health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.